
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HIVEP3 CRISPR/Cas9 KO Plasmid (h) | sc-410084 | 20 µg | $397.00 | |||
HIVEP3 HDR Plasmid (h) | sc-410084-HDR | 20 µg | $445.00 |
HIVEP3 (human immunodeficiency virus type I enhancer binding protein 3) encodes a large zinc finger transcription factor that binds κB-like DNA elements and modulates inducible gene expression programs downstream of inflammatory and stress signals. Through interactions with NF-κB–responsive regulatory regions, HIVEP3 contributes to control of cytokine-related transcriptional networks and broader immune cell signaling and differentiation processes. Perturbation of HIVEP3 expression or regulatory activity has been linked to dysregulated immune transcriptional states, making it relevant for studying mechanisms that couple enhancer/promoter binding to context-specific gene regulation. In biomedical research settings, HIVEP3 is commonly investigated in pathways governing transcriptional control, signal-dependent chromatin function, and immune-associated phenotypes.
HIVEP3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HIVEP3 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the HIVEP3 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, HIVEP3 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined HIVEP3 target site.
When co-transfected with HIVEP3 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the HIVEP3 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.